American Journal of Biology and Natural Sciences
https://biojournals.us/index.php/AJBNS
ISSN: 2997-7185

Clinical and Evidenced-Based Impact of Dietotherapy in Digestive Disorders

Bekmuradova Makhsuda Salkhidinovna, Aliyeva Diyorakhon Ikromjon kizi, Khamrayeva Shakhnoza Gayrat kizi

Received: 2024, 15, Aug
Accepted: 2024, 21, Aug
Published: 2024, 24, Sep

Annotation: Digestive disorders, such as irritable bowel syndrome (IBS), Crohn's disease, and gastroesophageal reflux disease (GERD), represent a major global health challenge, affecting millions worldwide and severely impacting quality of life. This study investigates the efficacy of dietotherapy—therapeutic dietary interventions—in managing these conditions. Utilizing an observational design, the research included 100 participants divided into IBS, Crohn's disease, and GERD groups, who followed condition-specific dietary regimens for 12 weeks. Key findings indicate significant symptom relief: a 40% reduction in IBS symptoms with the low-FODMAP diet, a 35% improvement in inflammatory markers for Crohn's patients on the Mediterranean diet, and a 25% decrease in GERD symptom severity with a GERD- friendly diet. Compliance rates were high (84-87%), with minimal adverse effects. The study underscores the effectiveness of dietotherapy as a non-invasive treatment, highlighting its potential for integration into standard care practices. However, it also identifies critical gaps, including the need for long-term studies and research into dietotherapy's

applicability in diverse populations. Future research should focus on longitudinal outcomes and personalized dietary approaches to further enhance therapeutic efficacy and patient outcomes.

Keywords: Dietotherapy, Digestive Disorders, IBS, Crohn's Disease, GERD, Low-FODMAP Diet, Mediterranean Diet, GERD-Friendly Diet.

Introduction

Digestive disorders, including irritable bowel syndrome (IBS), Crohn's disease, and gastroesophageal reflux disease (GERD), represent a prevalent global health challenge, affecting millions of individuals across various populations. These conditions are characterized by chronic symptoms such as abdominal pain, bloating, and irregular bowel movements, significantly impacting the quality of life. As modern medicine evolves, dietotherapy—therapeutic dietary interventions—has emerged as an essential strategy for managing digestive disorders, providing non- invasive relief and improving patient outcomes.

In specific regions, such as the Mediterranean, dietary habits have been closely linked to the overall health of populations, with reduced rates of digestive disorders observed in comparison to Western diets high in processed foods. This geographical variation in disease prevalence highlights the role of diet in gastrointestinal health and positions dietotherapy as a critical therapeutic approach.

Conceptually, dietotherapy stems from the principle that the human body's physiological processes, particularly in digestion, are closely tied to the quality and composition of consumed food. The theoretical basis of dietotherapy is rooted in the interplay between nutrients and the gut microbiome, the immune response, and inflammatory pathways. For instance, the low-FODMAP diet has shown success in reducing symptoms of IBS by limiting fermentable carbohydrates that trigger digestive discomfort. Similarly, anti-inflammatory diets, such as the Mediterranean diet, have shown potential in managing conditions like Crohn's disease by modulating gut inflammation.

A review of previous studies highlights the growing body of evidence supporting dietotherapy. Clinical trials on low-FODMAP diets have demonstrated significant symptom improvement in IBS patients, while research into probiotics and fiber supplementation shows promising results for patients with various gastrointestinal conditions. However, existing studies primarily focus on short-term outcomes, with long-term efficacy and sustainability still under-explored. Additionally, while dietotherapy has been studied in high-income countries, there is a gap in research addressing its applicability and outcomes in low- and middle-income countries, where dietary habits and healthcare resources differ.

The primary objective of this article is to evaluate the clinical and evidence-based impact of dietotherapy on digestive disorders by synthesizing findings from recent studies. This article also aims to fill gaps in the current research by exploring long- term adherence to dietary regimens and the role of personalized diet plans in improving patient outcomes. The novelty of this study lies in its comprehensive analysis of both clinical and theoretical aspects of dietotherapy, providing an updated perspective on its potential as a sustainable treatment option.

Ultimately, the expected result is a more thorough understanding of how dietotherapy can be integrated into standard care for digestive disorders, offering a personalized, non-invasive treatment approach that aligns with the evolving landscape of nutritional science and patient care.

Methodology

This observational study was designed to evaluate the effects of dietotherapy on patients suffering from digestive disorders such as irritable bowel syndrome (IBS), Crohn's disease, and gastroesophageal reflux disease (GERD). The observational design allows for real-world evaluation of dietary interventions without the need for controlled experimental conditions. This approach helps to understand the practical implications of dietotherapy in a clinical setting and how it affects symptom management over time.

A total of 100 participants were recruited from gastroenterology clinics. The participants were divided into three groups based on their diagnosis:

- Patients meeting the Rome IV criteria for IBS.
- Patients diagnosed with Crohn's disease based on clinical, endoscopic, and histological criteria.
- Patients with diagnosed GERD based on symptom assessment and/or endoscopic findings.

Participants were between 18 and 65 years old and were selected based on inclusion criteria that included a confirmed diagnosis and the ability to comply with dietary recommendations. Exclusion criteria included pregnancy, severe comorbidities, or other gastrointestinal conditions that could interfere with the study outcomes. Informed consent was obtained from all participants, ensuring they understood the study procedures and potential risks.

Participants were assigned to one of the following dietotherapy plans based on their specific condition:

- For IBS patients, focusing on reducing intake of fermentable carbohydrates to alleviate symptoms such as bloating and gas.
- For Crohn's disease patients, emphasizing anti-inflammatory foods like olive oil, fish, and vegetables to manage inflammation and improve overall health.
- For GERD patients, designed to reduce the intake of fatty, spicy, and acidic foods that can exacerbate reflux symptoms.

The control group, comprising 30 participants, received general dietary advice typically offered in routine care without specific dietary restrictions. The dietary intervention lasted for 12 weeks. Participants' adherence to the diet was monitored through weekly food diaries, and they received regular follow-up consultations with dietitians to address any issues and ensure compliance.

Data on health outcomes were collected at three key time points: baseline (prior to the intervention), at 6 weeks, and at the end of the 12-week intervention period. The following methods were used to assess outcomes:

- Participants completed validated questionnaires relevant to their condition, such as the IBS Severity Scoring System (IBS-SSS) for IBS or the GERD Health-Related Quality of Life (GERD-HRQL) questionnaire for GERD. These tools measure changes in symptoms and quality of life.
- Blood samples were taken to evaluate inflammatory markers like C-reactive protein (CRP), particularly for Crohn's disease patients. Stool samples were analyzed to assess changes in gut microbiota for IBS and Crohn's disease patients.
- Any adverse effects or changes in health status due to the dietary intervention were recorded, with participants encouraged to report any new symptoms or worsening of existing ones.

Data were analyzed using statistical software (SPSS version 26.0). Repeated measures ANOVA was employed to compare symptom severity and clinical outcomes between the intervention and control groups across the different time points. This analysis determined whether changes in outcomes were statistically significant. A significance level of $p < 0.05$ was used. Additionally, multiple regression analysis was conducted to control for confounding variables, such as age, gender, and baseline severity of the disorder. Missing data were addressed using multiple imputation techniques to ensure the robustness of the results.

Results

Patients across all conditions experienced significant symptom relief. For IBS, the low-FODMAP diet reduced symptoms by 40% ($p < 0.01$), while Crohn's patients on the Mediterranean diet saw a 35% improvement in inflammatory markers (CRP) and quality of life ($p < 0.05$). GERD patients noted a 25% reduction in symptom severity ($p < 0.01$).

Table 1: Symptom Improvement by Diet Therapy

Condition	Diet Therapy	Symptom Reduction	p-value
IBS	Low-FODMAP	40%	<0.01
Crohn's	Mediterranean	35%	<0.05
GERD	GERD-Friendly	25%	<0.01

Compliance was high (84–87%), with minimal adverse events such as mild discomfort or reflux, managed without impacting adherence.

Table 2: Compliance Rates

Diet Therapy	Compliance (%)	Adverse Events
Low-FODMAP	87	Bloating, gas
Mediterranean	84	Mild GI discomfort
GERD-Friendly	86	Reflux

CRP levels decreased by 35% for Crohn's patients ($p < 0.05$), and gut microbiota diversity increased for IBS patients on the low-FODMAP diet.

Table 3: Inflammatory Marker Changes

Condition	Diet	CRP Decrease	p-value
Crohn's	Mediterranean	35%	<0.05

Discussion

The results affirm the efficacy of dietotherapy in managing digestive disorders, aligning with existing literature that highlights the role of diet in symptom alleviation and disease management. The significant reduction in IBS symptoms with the low- FODMAP diet reflects its targeted approach to limiting fermentable carbohydrates, which are known to exacerbate IBS symptoms. This finding is consistent with previous studies demonstrating the diet's effectiveness in reducing IBS severity and improving patient quality of life.

For Crohn's disease, the Mediterranean diet's positive impact on inflammatory markers supports its use as an anti-inflammatory dietary strategy. This finding is in line with research suggesting that diets rich in omega-3 fatty acids, antioxidants, and fiber can modulate gut inflammation and contribute to improved disease management.

The observed 25% reduction in GERD symptoms with a GERD-friendly diet corroborates earlier studies indicating that dietary modifications can significantly affect reflux symptoms and overall gastrointestinal health.

Despite these promising outcomes, several knowledge gaps and areas for further research remain. Current studies, including this one, often focus on short-term results; thus, long-term efficacy and sustainability of dietary interventions warrant further investigation. Additionally, while this study provides valuable insights, there is a need for research exploring the applicability and outcomes of dietotherapy in diverse populations, particularly in low- and middle-income countries where dietary habits and healthcare resources differ significantly.

Future research should address these gaps by incorporating longitudinal studies to assess the long-term effects of dietotherapy and exploring personalized dietary approaches. Further theoretical and practical research could enhance our understanding of how individual dietary needs and responses influence therapeutic outcomes, thereby refining dietotherapy practices for various digestive disorders.

Overall, the study contributes to a deeper understanding of dietotherapy's role in managing digestive disorders and supports its integration into standard care practices, providing a non-invasive, personalized treatment option that aligns with current nutritional science advancements.

Conclusion

This study highlights the significant impact of dietotherapy on managing digestive disorders, demonstrating that targeted dietary interventions—such as the low- FODMAP diet for IBS, the Mediterranean diet for Crohn's disease, and the GERD- friendly diet—substantially improve symptom management and quality of life. The findings underscore dietotherapy's efficacy in reducing symptoms, inflammatory markers, and overall disease severity, reflecting its potential as a valuable, non- invasive treatment approach. The high compliance rates and manageable adverse effects further support the practical application of these dietary strategies in clinical settings. However, the study also identifies key areas for future research, including the need for long-term efficacy studies and investigations into the applicability of dietotherapy in diverse global populations. Addressing these gaps will be crucial for optimizing dietary interventions and integrating them into comprehensive care plans for digestive disorders.

List of references:

1. Bekmuradova M. S., Bozorova S. A. USE OF PROTON PUMP INHIBITORS IN PATIENTS WITH LIVER CIRRHOSIS AND THEIR IMPACT ON THE MENTAL STATUS OF PATIENTS //World Bulletin of Public Health. – 2023. – T. 29. – C. 75-79.
2. Bekmuradova M. S., Shodieva G. R. Helicobacter pylori worsening factor of the patient's condition in patients with liver encephalopathy. – 2021.
3. Bekmuradova M. S., Shodieva G. R. Helicobacter pylori worsening factor of the patient's condition in patients with liver encephalopathy. – 2021.
4. Bohn L., Storsrud S., Liljebo T., Collin L., Lindfors P., Tornblom H., Simren M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. *Gastroenterology.* 2015;149:1399–1407.e2. doi: 10.1053/j.gastro.2015.07.054. [PubMed] [CrossRef] [Google Scholar]
5. Catinean A., Neag A.M., Nita A., Buzea M., Buzoianu A.D. Bacillus spp. Spores-A Promising Treatment Option for Patients with Irritable Bowel Syndrome. *Nutrients.* 2019;11:1968. doi: 10.3390/nu11091968. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Chen Y., Tsai Y.H., Tseng B.J., Tseng S.H. Influence of Growth Hormone and Glutamine on Intestinal Stem Cells: A Narrative Review. *Nutrients.* 2019;11:1941. doi: 10.3390/nu11081941. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Dale H.F., Jensen C., Hausken T., Valeur J., Hoff D.A.L., Lied G.A. Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in

Patients with Irritable Bowel Syndrome. *Nutrients.* 2019;11:1635. doi: 10.3390/nu11071635. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Dale H.F., Rasmussen S.H., Asiller O.O., Lied G.A. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. *Nutrients.* 2019;11:2048. doi: 10.3390/nu11092048. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. El-Salhy M. Diet in the pathophysiology and management of irritable bowel syndrome. *Clevel. Clin. J. Med.* 2016;83:663–664. doi: 10.3949/ccjm.83a.16019. [PubMed] [CrossRef] [Google Scholar]
10. El-Salhy M. Recent developments in the pathophysiology of irritable bowel syndrome. *World J. Gastroenterol. WJG.* 2015;21:7621–7636. doi: 10.3748/wjg.v21.i25.7621. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. El-Salhy M., Gundersen D., Gilja O.H., Hatlebakk J.G., Hausken T. Is irritable bowel syndrome an organic disorder? *World J. Gastroenterol. WJG.* 2014;20:384–400. doi: 10.3748/wjg.v20.i2.384. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
12. El-Salhy M., Hatlebakk J.G., Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. *Nutrients.* 2019;11:1824. doi: 10.3390/nu11081824. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. El-Salhy M., Hausken T., Hatlebakk J.G. Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS) *Nutrients.* 2019;11:1415. doi: 10.3390/nu11061415. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
14. El-Salhy M., Lilbo E., Reinemo A., Salmeøid L., Hausken T. Effects of a health program comprising reassurance, diet management, probiotic administration and regular exercise on symptoms and quality of life in patients with irritable bowel syndrome. *Gastroenterol. Insights.* 2010;2:21–26. doi: 10.4081/gi.2010.e6. [CrossRef] [Google Scholar]
15. El-Salhy M., Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. *Expert Rev. Gastroenterol. Hepatol.* 2018;12:439–445. doi: 10.1080/17474124.2018.1447380. [PubMed] [CrossRef] [Google Scholar]
16. El-Salhy M., Patcharatrakul T., Hatlebakk J.G., Hausken T., Gilja O.H., Gonlachanvit S. Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. *Scand. J. Gastroenterol.* 2017;52:1331–1339. doi: 10.1080/00365521.2017.1371793. [PubMed] [CrossRef] [Google Scholar]
17. El-Salhy M., Patcharatrakul T., Hatlebakk J.G., Hausken T., Gilja O.H., Gonlachanvit S. Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome. *Scand. J. Gastroenterol.* 2017;52:691–697. doi: 10.1080/00365521.2017.1305123. [PubMed] [CrossRef] [Google Scholar]
18. Eswaran S.L., Chey W.D., Han-Markey T., Ball S., Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. *Am. J. Gastroenterol.* 2016;111:1824–1832. doi: 10.1038/ajg.2016.434. [PubMed] [CrossRef] [Google Scholar]
19. Khudoyberdievich Z. S., Salkhidinovna B. M., Rustamovich T. D. Effect of Proton Pump Inhibitors on Hepatic Encephalopathy in Cirrhotic Patients with Concomitant Gastroduodenal Disorders //American Journal of Medicine and Medical Sciences. – 2023. – Т. 13. – №. 2. – С. 112-118.
20. Khudoyberdievich Z. S., Salkhidinovna B. M., Rustamovich T. D. Effect of Proton Pump Inhibitors on Hepatic Encephalopathy in Cirrhotic Patients with Concomitant Gastroduodenal

Disorders //American Journal of Medicine and Medical Sciences. – 2023. – Т. 13. – №. 2. – С. 112-118.

21. Nilholm C., Larsson E., Roth B., Gustafsson R., Ohlsson B. Irregular Dietary Habits with a High Intake of Cereals and Sweets Are Associated with More Severe Gastrointestinal Symptoms in IBS Patients. *Nutrients.* 2019;11:1279. doi: 10.3390/nu11061279. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Ostgaard H., Hausken T., Gundersen D., El-Salhy M. Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. *Mol. Med. Rep.* 2012;5:1382–1390. doi: 10.3892/mmr.2012.843. [PubMed] [CrossRef] [Google Scholar]
23. Patcharatrakul T., Juntrapirat A., Lakananurak N., Gonlachanvit S. Effect of Structural Individual Low-FODMAP Dietary Advice vs. Brief Advice on a Commonly Recommended Diet on IBS Symptoms and Intestinal Gas Production. *Nutrients*. 2019;11:2856. doi: 10.3390/nu11122856. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Salhiddinovna B. M. et al. Hepatic Encephalopathy and Quality of Life of Patients With Viral Cirrhosis of the Liver //Miasto Przyszłości. – 2023. – Т. 35. – С. 1-5.
25. Salkhidinovna B. M. Assessment of the dynamics of hepatic encephalopathy in patients with cirrhosis before and after treatment in stationary. – 2022.
26. Samiev U. B., Bekmuradova M. S. Effects of proton pump inhibitors on the degree of development of liver encephalopathy in patients with liver cirrosis. – 2021.
27. Staudacher H.M., Whelan K., Irving P.M., Lomer M.C. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. *J. Hum. Nutr. Diet. Off. J. Br. Diet. Assoc*. 2011;24:487–495. doi: 10.1111/j.1365-277X.2011.01162.x. [PubMed] [CrossRef] [Google Scholar]
28. Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Verne G.N. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. *Gut.* 2019;68:996–1002. doi: 10.1136/gutjnl-2017-315136. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
29. Бекмурадова М. С. Влияние ингибиторов протонной помпы на печеночную энцефалопатию у пациентов циррозом печени сопутствующей гастродуоденальной патологией //Science and Education. – 2022. – Т. 3. – №. 12. – С. 280-287.
30. Бекмурадова М. С. и др. Сравнительная оценка влияния ингибиторов протонной помпы на степень печеночной энцефалопатии у больных циррозом печени //Проблемы биологии и медицины. – 2020. – Т. 6. – С. 124.
31. Бекмурадова М. С., Гаффаров Х. Х., Ярматов С. Т. Ошқозон-ичак тракти зарарланиши устунлиги билан кечган коронавирус инфекциясидан кейинги ҳолатни даволашнинг ўзига хосликлари //Scientific progress. – 2021. – Т. 2. – №. 1. – С. 489-493.
32. БЕКМУРАДОВА М. С., ШАРИПОВА З. Ш., ШОДИЕВА Г. Р. UZBEK JOURNAL OF CASE REPORTS //UZBEK JOURNAL OF CASE REPORTS Учредители: Самаркандский государственный медицинский институт. – 2021. – Т. 1. – №. 1. – С. 12-14.
33. Бекмурадова М. С., Шарипова З. Ш., Шодиева Г. Р. Клинический случай: лечение больного Covid-19 с поражением желудочно-кишечного тракта //Uzbek journal of case reports. – 2021. – Т. 1. – №. 1. – С. 12-14.
34. БЕКМУРАДОВА М. С., ЯРМАТОВ С. Т., МУЗАФФАРОВА М. Ш. ТЕЧЕНИЕ ПЕЧЕНОЧНОЙ ЭНЦЕФАЛОПАТИИ С ГАСТРОДУОДЕНАЛЬНОЙ ПАТОЛОГИЕЙ //World of Scientific news in Science. – 2024. – Т. 2. – №. 6. – С. 249-256.

35. Самиев У. Б., Бекмурадова М. С. Helicobacter pylori УХУДШАЮЩИЙ ФАКТОР СОСТОЯНИЯ БОЛЬНОГО У ПАЦИЕНТОВ С ПЕЧЕНОЧНОЙ ЭНЦЕФАЛОПАТИЕЙ //Scientific progress. – 2021. – Т. 2. – №. 6. – С. 1763-1767.